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There is much current concern (1-6) over
the suitability of animal species as surro-
gates for Homo sapiens in chemical safety
evaluation; one reason for this stems from
the finding that, compared to the fairly
large number (>400) of known rodent car-
cinogens (7-11), only a relatively small
number ofcompounds (-20-30) have been
shown to be carcinogenic in humans
(12,13). This has led to the view that small
mammalian species-such as those used
experimentally in, for example, the rodent
bioassay-are more susceptible to carcino-
genicity than are human populations.
Although the reasons for this disparity may
be due to the fact that rodent carcinogenici-
ty test procedures involve life-span studies
with the chemical administered at its maxi-
mum tolerated dose (MTD), whereas
human exposure is not normally under con-
trolled conditions, the variation in body size
could represent one factor in differential
tumor susceptibility, as has been shown for
diethylnitrosamine in various animal species
(14). Furthermore, there are many exam-
ples of marked species differences (15) in
the toxicity offoreign compounds, with one
particular animal model representing a dos-
er paradigm to Homo sapiens than another
depending on the chemical concerned.
Although there may be many reasons for
these differences, it is likely that some may
be traced to variations in primary metabo-
lism between species in which the
cytochrome P450 (CYP) mono-oxygenases
are mainly involved (16-19).
Xenobiotic metabolism is generally
regarded as proceeding via two stages, Phase
I and Phase II; the initial oxidative stage in
Phase I is followed by conjugation by a sec-
ond dass ofenzyme, usually referred to as a
conjugase. Over 90% of Phase I metabo-
lism is mediated by cytochromes P450, a
superfamily of heme-thiolate enzymes of
which over 750 individual members have
now been characterized in terms ofgene or
protein sequence data (20-23); only 36
human P450s have been sequenced to date,
whereas in the rat, 47 P450s are known
from isolated cDNAs, etc. In mammals,
exogenous metabolism occurs mainly in the
liver, which also represents the major site of
P450 proteins, although smaller concentra-
tions are found in other organs and tissues.
Apart from those isoforms primarily associ-
ated with endobiotic metabolism, hepatic
microsomal P450s comprise members of
families CYP1, CYP2, and CYP3, ofwhich
the CYP2 family possesses five main sub-
families, CYP2A through to CYP2E. The
CYPI family contains two major isozymes,
CYPlA1 and CYP1A2, which appear to be
highly conserved across most animal species
in terms ofprimary sequence homology, as
is the CYP2E subfamily (19,22,24). The
major xenobiotic-metabolizing P450 iso-
forms in five mammalian species are shown
in Table 1.
It is generally recognized that induction
of P450s associated with metabolic activa-
tion (e.g., CYPIA and CYP2E) is also
regarded as indicative of potential toxic-
ity/carcinogenicity (25-27). However,
CYPlAI, an isoform most dosely associated
with the activation ofprocarcinogens [such
as benzo(a)pyrene] in small rodents and
readily inducible by polycyclic aromatic
hydrocarbons (PAHs) and 2,3,7,8-tetra-
chlorodibenzo-p-dioxin (TCDD), is poorly
expressed in human liver (28) and, conse-
quently, is not likely to be of relevance to
human hepatocarcinogenicity. Nevertheless,
CYPlAI is expressed in human lung (28)
and also has been shown to be readily
induced by procarcinogenic PAHs, induding
those present in cigarette smoke and exhaust
emissions, thus constituting a potentially
important factor in pulmonary carcinoma.
CYP1A2, however, is involved in the meta-
bolic activation ofpolyaromatic and hetero-
cyclic amines and amides, such as those
formed during the cooking ofmeat products;
this form is both present and inducible in
human liver (28) as well as in liver ofexperi-
mental animals species. Consequently,
although CYPIA and CYP2E subfamilies are
well conserved across mammalian species,
variations in their expression/induction and
its consequences [reviewed byLewis (23)] can
explain some of the examples ofspecies dif-
ferences in the metabolism and activation of
potentially toxic chemicals such as butadiene
(29). CYP2E, for example, is inducible by
low molecular weight compounds such as
benzene, ethanol, acetone, carbon tetrachlo-
ride, and dichloromethane; it appears that
many of the toxic consequences of CYP2E
induction are due to theassociatedgeneration
of reactive oxygen species (ROS) (27,30).
There is evidence to suggest that small
rodents such as the mouse (31) are more sus-
ceptible to the toxic/carcinogenic effects of
ROS production often associated with
CYP2E induction (32). Although there is
some relationship between ROS-mediated
toxicity and body weight (33) in which
species life span could also be a factor (34),
the increasedsusceptibility ofsmall rodents to
ROS relative to the situation in Homo sapiens
may be due to the fact that glutathione
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their cellular GSH on exposure to ROS-gen-
erating chemicals (35) but not in humans,
Table 1. P450isoforms in various mammalian speciesa
CYP Human Monkey Rabbit Rat Mouse
1A 1A1,1A2 1Al, 1A2 1A1, 1A2 1A1, 1A2 1A1, 1A2
2B 2B6 2B17 2B4,22B5 2B1,2B2,22B3 2B9,2B10,2B13
20 206 2D17 2D1,2D2,2D3, 2D9,2D10,2D11,
2D4,2D5 2D12,2D13
3A 3A4,3A5 3A8 3A6 3A1,3A2,3A9 3A11,3A13,3A16
CYP, cytochrome P450subfamily;-, noinformation available todate. Data from Nelson etal.(224.
'hese arefound predominandy, butnotexclusively, inthe liverofthe relevantspecies.
Table2. Known carcinogens activated byhuman P450 enzymes
CYP1A1 CYP1A2 CYP2A6 CYP2E1 CYP3A4
BaP PhIP DMN Benzene Aflatoxin B1
PhIP Glu-P-1 DEN Styrene Aflatoxin Gl
PAHs Glu-P-2 NNK Acrylonitrile Sterigmatocystin
IQ NNN Vinylcarbamate BaP-7,8-diol
MelQ NNAL Vinylchloride Estradiol
MelQx Vinyibromide 6-Aminochrysene
Trp-P-2 Ethylcarbamate Senecionine
4-Aminobiphenyl Trichloroethene MOCA
2-Naphthylamine Carbon tetrachloride Tris-(2,3-DPP)
2-Aminofluorene Chloroform
2-AAF DMN
NNK DEN
NNK
NNN
NNAL
Butadiene
Abbreviabons: BaP, benzo(a)pyrene; PAHs, polyaromatic hydrocarbons; PhIP, 2-amino-1-methyl-6-phenylimidazo-(4,5-b)pyri-
dine; Glu-P-1,2-amino-6-methyl-dipyrido(1,2-a.3,2'-dfimidazole; Glu-P-2,2-aminodipyrido(1,2-ar.3,2'-d)imidazole; IQ 2-amino-3-
methylimidazo(4,5-t4quinoline; MelQ, 2-amino-3,5-dimethylimidazo(4,5-4quinoline; MelQx, 2-amino-3,5-dimethylimidazo(4,5-
tquinoxaline; Trp-P-2, 3-amino-1-methyl-5H-pyrido(4,3-b)indole; 2-AAF, 2-acetylaminofluorene; NNK,4-(methyinitrosamino)-
1-(3-pyridyl)-1-butanone; DMN, N-nitrosodimethylamine; DEN, N-nitrosodiethylamine; NNN, nornitrosonicotine; NNAL, 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanol; MOCA,4,4'-methylene bis(2-chloroaniline); DPP,dibromopropylphosphate.
Data from Guengerich (96.1
Table3. Current procedures for chemical safety evaluation
Category Tests
Long-term tests
Short-term tests
Rodenttwo-species carcinogenicity bioassay (2years)
Repeated dosetoxicity study(1 year)
90-Day exposure
14-Day exposure
Reverse mutation assay (Ames testformutagenicity)
Micronucleus test(induction of micronuclei in bone marrow)
Chromosomal aberration
Sister-chromatid exchange
Acute toxicitystudy
Physicochemical measurements (log Pocr water solubility, pKa, melting
and boiling points, vapor pressure)
Enzyme induction study (ENACT procedure)
Computer-based tests Electronic structure calculation (via molecular orbital procedures)
Quantitative structure-activity relationship (GSAR) study
Calculation oflog P t, pKa, log D and molecularweight (Pallas System)
Structural alertana?ysis (DEREK system, CASE,TOPKAT, etc.)
Evaluation of P450-mediated activation (COMPACTsystem)
Abbreviations: DEREK, deductive estimate of risk from existing knowledge; TOPKAT, toxicity prediction by computer-
assisted technology; ENACT, enzyme activation in chemical toxicity; CASE, computer-automated structure evaluation;
COMPACT, computer-optimized molecular parametric analysis ofchemicaltoxicity.
where epoxide hydrolase is employed in
order to conserve GSH levels.
The xenobiotic-metabolizing P450s can,
in fact, be regarded as a double-edged sword
in respect to activation and detoxication of
chemicals, as some forms (particularly
CYPIA1/2 and CYP2E1) are able to mediate
in the activation ofprocarcinogens (19,36) as
shown in Table 2, whereas others are largely
associated with detoxifying metabolism
(21,37). Moreover, it is possible to trace
species differences in xenobiotic metabolism
to variations in P450 levels, their inducibii-
ties, and the existence ofdifferent P450 iso-
forms ofthe sameprotein family orsubfamily
in various mammalian species (19,23).
However, it is difficult to make meaningful
comparisons between xenobiotic metabolism,
and hence toxic activation/detoxication of
carcinogens, andotherforeigncompounds, in
humans and experimental animal species due,
in part, to the differences between the P450s
involved and the way in which theirlevels are
affected by factors such as age, sex, diet,
genetics, pathophysiological status, tissue
specificity, and environment, for example
[reviewedbyGibsonandSkett(38)].
Laboratory-bred rodent species such as
the rat and mouse tend to be genetically
pure strains and therefore are unlikely to be
subject to the considerable interindividual
variation in P450 complement that is
apparent in human ethnogeographical pop-
ulations (39). Furthermore, there is little
comparison even between rats and mice
with respect to chemical carcinogenicity
(40) and in the metabolic pathways for
both activation and detoxication.
Moreover, there are notable sex and strain
differences with respect to the way in
which chemicals are metabolized (and
therefore activated or detoxified) by the
same rodent species (41). Pure laboratory
strains may exhibit such differences in
metabolic activation as a result of diet
and/or environment because these factors
can lead to significant changes in P450
complement and inducibility, in addition
to alterations in other enzymes and pro-
teins relevant to toxic activation (24).
However, in some cases, the metabolism of
a particular chemical may be similar
between, for example, one rodent species
and Homo sapiens, whereas there are also
many examples ofsignificant species differ-
ences. Tamoxifen, a therapeutic agent used
in the treatment of breast cancer, is a
known carcinogen in rodents and other
experimental animal species, but it is gener-
ally regarded as being largely safe in
humans (42). The reason for the species
difference is mainly due to the way in
which tamoxifen is metabolized in humans
as opposed to the situation in rats and
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(GSH) is used as a radical scavenger in
rodents, thus leading to a rapid depletion of
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mice. Tamoxifen is readily metabolized by
CYP2C9 and CYP3A4 isoforms in Homo
sapiens, which leads to its relatively rapid
elimination in human subjects. However,
different P450 families and subfamilies
appear to be involved in the metabolic acti-
vation of tamoxifen in rodents; this may
involve the formation of an epoxide (a
highly reactive electrophilic species),
although other activating pathways exist,
which are also P450-mediated, such as
ethyl group hydroxylation and subsequent
formation ofa carbonium ion intermediate
that is able to interact covalently with
DNA, thus giving rise to genotoxicity and,
eventually, to carcinogenesis (42).
In addition to these differences in the
P450s themselves, the levels of the various
isoforms differ markedly between species
and are also subject to different regulatory
mechanisms. Furthermore, experimental
animals are maintained in a strictly con-
trolled environment under specific dose reg-
imens and dietary restrictions (43-45),
which is in complete contrast to the situa-
tion experienced bythe majority ofhumans.
As an individual's complement ofthe drug-
metabolizing P450s is subject to their degree
ofmedication, lifestyle, pathophysiological
state, and level ofinvoluntary exposure to
potentially toxic chemicals in the environ-
ment, in addition to other factors such as
diet, age, sex, ethnicity, andpossible in-born
metabolic defects (i.e., genetic polymor-
phism), it is probably unwise to attempt any
extrapolation from the effects observed in
experimental animals to a likely scenario
encountered in human metabolism.
However, recent advances in molecular bio-
logical techniques that enable the stable
expression ofhuman P450s in heterologous
systems, together with test procedures for
genotyping an individual's P450 comple-
ment, point the way forward to future
chemical safety evaluation whereby medical
practitioners could be in a position to advise
on specific treatments for disease states and
other conditions based on a knowledge of
the patients' enzyme activities and metabolic
competence (23).
Current Procedures for
Chemical Safety Evaluation
A variety of methods (46-52) have been
developed for the risk assessment and safety
evaluation ofchemicals destined for human
exposure and can be broadly dassified into
three main categories: long-term or life-
span studies, short-term procedures, and
computer-based tests, as shown in Table 3.
Long-termTest Procedures
The rodent carcinogenicity bioassay (53)
represents the traditional method for the
screening ofchemicals for potential toxicity
and involves the use of two rodent species
(rat and mouse) as surrogates for humans.
The rodent bioassay comprises life-span
studies on both sexes ofrat and mouse, usu-
ally at three dose levels, based on the MTD
(53). Ideally, for a chemical to be regarded as
carcinogenic in at least one segment ofthe
rodent assay, there should be a dose-depen-
dent increase in tumor burden relative to the
control group. However, for various reasons,
this criterion is not rigidly adhered to, as can
be appreciated from a careful inspection of
the National Toxicology Program (NTP)
compilations ofcarcinogenicity bioassays, for
example. Furthermore, the site of tumor
incidence (or multiplicity) appears to be
another factor in determining whether a
chemical is regarded as a carcinogen because
unusual or rare cancer sites tend to be given
less weight than those that occur, for exam-
ple, in the liver orkidney.
Due to differences in the metabolism of
certain chemicals between rats and mice,
there is often little or no concordance for
rat and mouse carcinogenicity data (40).
Moreover, gender variations in the xenobi-
otic metabolizing enzymes are the likely
cause of the low correlation between sexes
within the same rodent species, and the sex
differences in P450s has been well estab-
lished in the rat and mouse. It is thus possi-
ble to rationalize some of the sex and
species differences in xenobiotic metabolism
and carcinogenic activation/detoxication in
terms of altered levels of P450 isozymes,
their variation in inducibility in different
organs and tissues of different mammals,
and their isoform specificities, which exhib-
it either a dominance or preference in dif-
ferent sexes and species.
A further genetic factor must be consid-
ered when attempting to extrapolate find-
ings based on rodent studies to the human
condition. This is the additional complica-
tion of genetic polymorphism in human
ethnogeographical populations, some of
which pertain to P450 enzymes such as
CYP2D6 (54) and CYP2E1 (30), for exam-
ple. It is not possible to identify chemicals
that may be inadequately cleared in certain
percentages of human subjects on the basis
of experimental findings arising from tests
carried out in rodents or, indeed, in any
other mammalian species, including other
primates. Furthermore, P450 isozymes from
the samefamily orsubfamily but in different
species may metabolize the same chemical
differently, even though the P450s con-
cerned may be highly homologous, because
even asingle amino acidchange can dramat-
ically alter the enzyme's substrate specificity
or regioselectivity of metabolism as in
CYP2A, forexample (55,56).
Two chemicals that may serve as exam-
ples are coumarin and butadiene; both of
these are metabolized differently between
rodent species and are activated in one
species but not in the other. Coumarin is
metabolized in the rat via 3,4-epoxidation,
which represents an activating pathway
because coumarin is a carcinogen in this
species (55). However, in the mouse,
coumarin undergoes 7-hydroxylation, which
is considered to be adetoxifyingpathway. As
far as butadiene is concerned, the opposite
situation occurs (29). In the mouse, this
chemical is a carcinogen via P450-mediated
activation to the mono- and diepoxide,
whereas, in the rat, butadiene is noncarcino-
genic because the diepoxide is not formed. It
is possible to trace both ofthese species dif-
ferences to alterations in the P450s involved
in the metabolism of the two chemicals;
interestingly, in these examples, the situation
in humans resembles that shown in the
mouse rather than in the rat, although there
are manyother cases inwhich the opposite is
found and others in which neither rodent
species mimics thehuman situation.
The main reason for these species differ-
ences in carcinogenicity probably involves
the relevant P450 isozymes that metabolize
the compounds concerned. For coumarin,
the major route ofmetabolism in humans,
i.e., the 7-hydroxylation, is catalyzed by
P4502A6 (CYP2A6), whereas the analogous
mouse ortholog is CYP2A5, which mediates
the same metabolic pathway. However, in
the rat, the CYP2A1 isoform facilitates for-
mation ofthe carcinogenic 3,4-epoxide, and
this signiflcant species variation can be
explained by molecular modeling ofthe rele-
vant enzymes' active sites (55). Similarly, the
species differences in butadiene metabolism
can be rationalized by active site modeling of
the CYP2E1 enzymes from rats, mice, and
humans (55).
It can be argued that the use of small
rodents as surrogates for humans is scientif-
ically flawed due to fundamental differ-
ences in the metabolizing enzymes in the
mammalian species. The <50% concor-
dance between rat and mouse and between
male and female in each species serves to
diminish confidence in the rodent bioassay;
there is also little correlation with human
epidemiological studies for carcinogenicity.
The enormous expense of the 2-3 year
rodent bioassay (approaching $1 million
per chemical) provides an additional incen-
tive to investigate complementary short-
term and noninvasive methods for the
screening offoreign compounds.
Short-term Test Procedures
Partly as a result of the escalating costs of
life-span and other long-term studies,
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together with concerns over their essentially
ritualistic nature, an increasing number and
variety of short-term in vivo and in vitro
procedures have been developed over the
past 30 years or more (57-61). A selection
of these short-term tests are listed in Table
3; these bear relatively lower costs in com-
parison with life-span rodent bioassays and
other long-term tests.
These short-term procedures tend to
focus on monitoring individual stages that
lead the development of carcinogenicity
and other related toxic responses to chemi-
cal insult. For example, the Ames test for
bacterial mutagenicity has been used for
some time as a guide to the genotoxic
nature of a particular chemical in mam-
malian systems (62). The modification
known as an S9 mix represents an attempt
to more effectively reproduce the likely
activation/detoxication mechanisms that
could occur in mammals. Although this
significant improvement of the technique,
which makes use of mammalian microso-
mal P450s induced by Arochlor 1254, can
be expected to give rise to satisfactory con-
cordances with, for example, rodent car-
cinogenicity, the concordance between the
two procedures is disappointingly low,
around 55% overall and, in a recent study
(63), correlations were less than 40%
between mutagenic potency (revertants per
mM/l/plate) and carcinogenic potency
(increased tumor risk per mM/kg/day).
However, these correlations could be
improved to just over 60% when fewer
chemicals were considered (63).
Nevertheless, the low cost and straight-
forwardness ofthe Ames test has led to its
general adoption as a standard technique
for assessing the potential genotoxicity of
chemicals destined for human exposure.
Indeed it is useful and informative to estab-
lish whether the carcinogenicity of a com-
pound is made manifest via a genotoxic
mechanism, either bydirectly reacting with
DNA (48,64,65) or as a result ofenzymic
activation; the comparison between Ames
tests conducted with or without S9 will
facilitate this, and ifboth are negative, the
chemical concerned can then be regarded
as a nongenotoxic carcinogen. The ways in
which carcinogenicity may be in evidence
without genotoxicity include receptor-
mediated events such as those produced by
peroxisome proliferators, by estrogenic
compounds, and by chemicals such as
TCDD, which are potent inducers of
cytochrome P4501 (CYPI) via high-affini-
ty binding to the cytosolic aryl hydrocar-
bon (Ah) receptor (26). In fact, the estro-
gen receptor and peroxisome proliferator-
activated receptor are both members ofthe
steroid hormone receptor superfamily and
are involved in promoting cell growth,
whereas the Ah receptor is another type of
nuclear receptor, which is also associated
with increased cell division following
translocation to the nucleus of its ligand-
bound complex. All of these receptors,
however, bind to specific DNA response
elements in the regulatory (noncoding)
regions of particular genes associated with
the production ofenzymes and other pro-
teins involved in cell proliferation (23,38).
ENACT (enzyme activation in chemical
toxicity), a short-term procedure related to
the modified Ames test (i.e., involving an
activation system), is associated with P450
enzyme induction (27); in contrast to the in
vitroAmes test, ENACT uses a small num-
ber of animals to assess the ability of a
chemical to raise the levels of some key
P450 isozymes that have been associated
with toxic effects. By measuring the extent
of induction at differing dose levels, it is
possible to establish whether the particular
increase in the P450 concerned is dose
dependent, such that dose-response rela-
tionships can be formulated. This is useful
for establishing the inducing ability of the
chemical, thus providing a possible estimate
ofthreshold exposurelevels inhumans.
There is satisfactory agreement between
the Ames test (with S9 mix) and enzyme
induction studies in some cases (25,26),
whereas either or both of these procedures
are sometimes in line with carcinogenicity
data for certain chemicals. There are also
examples where the results of these tech-
niques can be explained in terms of the
molecular or electronic structures of the
compounds themselves (66). Furthermore,
both the Ames and ENACT tests produce
numerical values that allow the data to be
analyzed via quantitative structure-activity
relationship (QSAR) studies, whereby cor-
relations are sought between biological
activity and one or more descriptor vari-
ables that may come from either a physico-
chemical measurement or a computer-
assisted evaluation ofthe chemicals' molec-
ular and/or electronic structures (67-75).
Such QSAR procedures, which also involve
the use of statistical methods for assessing
correlations between what may be a rela-
tively large number ofparametric variables,
can be extremely helpful in both formulat-
ing a rational description ofpotency differ-
ences within series ofrelated chemicals and
in providing a means for predicting the
likely activity/toxicity of untested com-
pounds (68,69,76). There are several
descriptor variables often found to be
involved in the explanation ofdifferences in
toxicityand other forms ofbiological activi-
ty for many classes of chemicals (68):
octanol-water partition coefficient (log
P.,); water solubiity; acid-base dissociation
constant (pKa); molecular weight; vapor
pressure; molar refractivity; molar polariz-
ability; superdelocalizability; molecular
orbital energies (HOMO, highest occupied
molecular orbital; LUMO, lowest unoccu-
pied molecular orbital); dipole moment;
molecular electrostatic potential/electrostatic
isopotential (MEP/EIP); and electron densi-
ties/atomic charges. As far as the oil/water
partition coefficient (and the related
octanol-water partition coefficient; Poct) is
concerned, there are numerous examples of
the use of this estimate of compound
lipophiicitybeingcorrelatedwith changes in
biological potency for large numbers of
structurally related series of chemicals
(77,78). However, the frontier orbital ener-
gy, E(LUMO), frequently appears in QSAR
expressions involving chemical toxicity; there
are also instances where the E(HOMO)
value, or the combined parameter AE [AE =
E(LUMO) - E(HOMO)] correlate closely
with both carcinogenicityand otherforms of
toxicity, particularly those associated with
P450-mediatedevents (76).
Computer-basedTests
Use ofcomputers has made a huge impact
on virtually all aspects of modern living.
However, the employment of computer
technology in toxicity screening has always
been a controversial subject for various rea-
sons (79), including a considerable suspi-
cion of computer-generated data by many
toxicologists and the difficulty of directly
relating molecular structural parameters to
a biological end point, which can often
involve several sequential stages and maybe
susceptible to a variety oflargely external
factors such as environment, diet, and dose
regimen, forexample.
The attraction of using computers in
toxicity testing is obvious to most scientists
involved in the safety evaluation ofchemi-
cals destined for human exposure and for
hazard identification of substances in the
environment. There are several advantages
of computer-based procedures: they are
rapid, relatively inexpensive, and always
reproducible, and they allow researchers to
avoid the need for actual chemical synthesis
and any form of experimentation (80).
However, care needs to be exercised in
interpretating computer-generated results;
for example, the outcome of QSAR analy-
ses can, under certain circumstances, be
misleading in terms of overinterpretation
of inadequate or insufficient data.
Nevertheless, as a tool used with other
noninvasive in vitroprocedures, some com-
puter methods (see Table 4) for toxicity
testing can be extremely helpful in pre-
screening chemicals and for prioritization
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oflarge numbers ofcompounds for further
evaluation using short-term procedures
(81). Moreover, there have been many
examples which demonstrate that comput-
er-based evaluations can explain the find-
ings of biological studies, including the
rodent carcinogenicity bioassay; in some
cases, these are able to provide a satisfactory
level ofprediction, which can be as high as
about 70%. Indeed, the employment of a
battery of computer tests and other short-
term procedures could prove extremely use-
ful as an alternative to the life-span rodent
bioassay. Many groups of investigators
worldwide are currently involved in devel-
oping a variety of computer methods for
the prediction ofcarcinogenicity (69,81).
Species Differences Relating
to P450 Variations
A potential difficulty emerges, however,
when one has to consider the possible effects
of species differences in metabolism and
toxic response ofchemicals. Extrapolation of
experimental data from small rodents and
other mammalian test species to Homo sapi-
ens is not always straightforward, although
there can be an approximately linear rela-
tionship between activity and species body
weight; more frequently, such relationships
tend to be nonlinear but may, nevertheless,
be amenable to statistical analysis. Nonlinear
relationships between, for example, Phase 1
metabolism and species body weight are
often due to orthologous P450s in those
species, differential distribution ofthe P450
isoforms responsible for bioactivation,
and/or a variation in mechanism that may
involve different P450 families or subfami-
lies. Such considerations can be addressed,
albeit partially, by molecular modeling of
the P450 isozymes involved in chemical
metabolism, but such procedures are in the
early stages ofdevelopment (23). However,
the metabolism oftamoxifen in Homo sapi-
ens, for example, can be explained bymodel-
ing the interaction of this substrate within
the active sites of the P450s involved, thus
demonstrating the potential for a technique
that can predict the likely metabolic fate of
an untested chemical even before synthesis.
The success ofprocedures such as these for
exploring all metabolic and toxic possibili-
ties for a new compound, which may be
intended for use as a therapeutic agent,
requires the detailed structural analysis of
every enzyme or protein that could be
involved in metabolism or toxic activation;
this necessitates carrying outcrystallographic
and/or nudear magnetic resonance (NMR)
studies on at least one protein in each class
such that a reasonable homology model can
be constructed. Benigni and coworkers
(82,83) have stressed that the importance of
Table4. Comparison betweenfourcomputer-based methodsoftoxicityevaluation
Methods
and characteristics COMPACT DEREK HazardExpert TOPKAT
Molecularstructure 3D 2D only 2D only 2D only
Metabolism + - +
L -:P. - .-- .* + +
pKa + +
Molsogle intractfions. + . ...- .:.- ::. .:
QSAR + +
Hardware Any VAX/Unix PC PC
No. ofatoms 350 64 Limited by PC Limited by PC
Knov4odojase P450interactions FDA EPA (1SARINCI
Publications >30 >5 >5 >10
.1.0 ~ 17 10 Li. . :.:. . : 1.0 : :: : : 7 .. ... ....... ;. .7 :., e.. :~~~~~~~~~~~~~~~~~..
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the biological activity data is often over-
looked in QSAR studies because scientific
scrutiny tends to become focused on the
structural descriptors and their statistical sig-
nificance. The normally wide variation and
margins of error in the biological data are
usually disregarded in the search for appar-
endyhighlysignificant correlations.
For drug metabolism via P450 isozymes,
the following examples serve to illustrate the
importance of considering the metabolic
pathways and enzymes involved. First, the
metabolism ofhexobarbital has been studied
in various mammalian species, and the
results are shown in Table 5. In this case, the
half-life ofthedrug(t112) exhibits agoodcor-
relation (r= 0.83) with bodyweight (W) for
the five species, provided that the raw data
are converted into their logarithmic form.
The relationship (shown in Fig. 1) then
becomes as follows:
logtl/2 = 0.323 (± 0.127) logW + 1.994,
where n = 5; standard error (SE) = 0.336; r=
0.8256; F(variance ratio) = 6.42.
Hexobarbital is metabolized by P450s
of the CYP2B and CYP2C subfamilies in
the rat and humans, so it may be reason-
able to assume that these are also involved
the mouse, rabbit, and dog, in which barbi-
turates tend to exhibit induction of both
subfamilies, with a preference for CYP2B
(84). Although CYP2B isozymes are
inducible in both rodents and in rabbits,
this is not the case in Homo sapiens; in
humans, the level ofthe CYP2B6 ortholog
is extremely low in hepatic tissue (85) and
Table 5. Metabolic half-lives(t1,2) of hexobarbital
in five mammalian species
Species t112(min) Bodyweight(kg)
Mouse 19 0.025
Rabbit 60 2.5
Rat 140 0.20
Dog 260 5.0
Human 360 68.0
Data from Pratt and Taylor(94.
is apparently poorly induced by phenobar-
bital and other barbiturate drugs, which is
in complete contrast with the situation in
rats, mice, and rabbits (84). Such consider-
ations may explain the relatively long half-
life in humans where the CYP2C subfamily
ofisozymes, particularly CYP2C19, appear
to be the major catalysts of hexobarbital
metabolism (86).
Second, omeprazole metabolism has
been studied in several mammalian species,
and theclearance data are presented in Table
6. In Homo sapiens, the major route of
metabolism appears to be a methyl hydroxy-
lation step, which is primarily catalyzed by
CYP2C19, a known polymorphic isoform;
however, CYP3A4 is also involved in
omeprazole metabolism, and being the main
component ofhuman liver P450, this path-
way represents an important secondary route
ofomeprazole dearance in humans (87).
There is significant variation in the
complement of P450 isoforms between
Homosapiensand other mammalian species.
For example, CYP2B is well conserved
between rodents and rabbits, but is poorly
expressed in human liver. In contrast,
CYP3A represents the major component of
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Figure 1. A plot of log half-life (t112) versus log
body weight (kg) for hexobarbital metabolism in
five mammalian species.
Table6.Speciesvariation in omeprazole clearance
Intrinsic Bodyweight
Species clearance (1/min) (kg)
Rat 0.52 0.25
Rabbit 0.96 2.0
Dog 3.40 15.0
Human 3.65 67.0
Datafrom Okudaira etal. (95).
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Figure 2. A plot of intrinsic clearance (I/min)
against bodyweight (kg) for omeprazole metabo-
lism in four mammalian species.
human hepatic P450 although the levels of
this subfamily are generally quite low in
other species, especially in experimental ani-
mals. The CYP2C subfamily in humans
possesses distinctly different isoforms that
exhibit varying substrate specificity, and
human CYP2C19 is subject to genetic
polymorphism. Consequently, although
hexobarbital is likely to be metabolized in
thesameposition in mostmammalian species
via CYP2B and/or CYP2C subfamily media-
tion, the metabolism of omeprazole and
tamoxifen, for example, is more complex,
withseveral Phase 1 pathways beingmediated
by different P450s. The data presented in
Tables 5 and 6 indicate that there is ageneral
Figure 3. A decision tree approach to the safety evaluation of chemicals. Abbreviations: MW, molecular
weight; a/i&, area/depth2; EIP, electrostatic isopotential; QSAR, quantitative structure-activity relation-
ship; ppar, peroxisome proliferator-activated receptor.
relationship between rate ofmetabolism and
body weight, but because of the different
P450s involved and their altered levels
between species, the relevant metabolic rate
changes from animals to humans depend on
the nature ofthechemicalbeingmetabolized.
For omeprazole intrinsic dearance (CLm,t)
in the four mammalan species, a log-log rela-
tionship with bodyweight also holds, but the
bestfitwiththedatais givenbythefollowing
=int = 4.077 (± 0.355) W/(4.635 + W),
where n = 5; SE = 0.034; r= 0.988; F= 81.8.
Figure 2 presents this relationship for the
species in question; the relationship is
approximately linear with body weight for
the three animal species but exhibits a
marked nonlinearity when the human data
are considered. The increased rate of
omeprazole clearance in man is probably
due to the mediation of CYP3A4, as this
represents such a major component of the
hepatic P450 complement, in contrast with
other mammalian species in which enzymes
of this family constitute only a small per-
centage oftotal P450 in the liver. Although
the main route ofomeprazole metabolism is
through the CYP2C19 isoform in Homo
sapiens, this isozyme represents only a rela-
tively minor proportion of the human
hepatic P450 complement.
Conclusions
Consequently, the extrapolation of animal
data to humans is not always simple and
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straightforward due to species differences in
the P450 enzymes present, including their
active site differences, which mayeven occur
within enzymes of the same family or sub-
family. A review by Smith (16) provides fur-
ther examples of such species differences in
metabolism that can also be explained in
terms of P450s and describes many impor-
tant aspects ofpharmacokinetics. In particu-
lar, the relevance oflogD7.4 (D is the distri-
bution coefficient) values were shown to be
potentially useful for differentiating between
substrates of different P450 isozymes, pri-
marily CYP3A, CYP2C, and CYP2D iso-
forms, as these constitute the P450 enzymes
in human liver that metabolize the large
majority of currently used pharmaceuticals,
although log D is also of importance in
the context ofPhase II metabolism.
The log D74 parameter is, in fact, the
lipophiicity (log P) ofa chemical that is ion-
ization-corrected for a pH medium of7.4, as
this represents the most commonly usedvalue
forphysiological pH. The expressions relating
these quantities forcompounds thatare ioniz-
ablecanberepresented in thefollowingway:
logD7.4 = logP - log (1 + 1074-PKa) foracids
log D74= log P - log (1 + 10PKa-7.4) forbases
Consequendy, it is relatively straightforward
to evaluate the log D74 for any compound
from the neutral log P value and pKa, pro-
vided that such information is available. It is
important to use logD7.4 instead oflog P for
the estimation of compound lipophilicity
because ionizationwill diminish theobserved
lipophiic character of a chemical, provided
that the compound contains groupings that
may become partially ionized at physiologi-
cal pH. Because log P is one ofthe major
physicochemical parameters used in the safe-
ty evaluation of chemicals destined for
human exposure, the potential for ionization
is extremely relevant, particularly where
P450-mediated metabolism is possible; this
can provide an early indication ofprobable
P450 isoform specificity. Furthermore,
lipophilicity of a chemical plays an impor-
tant role in its biological fate in almost all
species, induding Homo sapiens, because this
factor determines the bioavailability and
bioaccumulation effects of the compound
itself, and biological half-lives are often dose-
ly related to lipophilic potential (88).
Therefore, from a compilation ofshort-term
test data, physiochemical parameters, and
molecular structural information, it should
be possible to assess the likely risk to human
health from exposure to a given substance;
such procedures are currently under develop-
ment in this laboratory and elsewhere.
Figures 3 and 4 represent examples ofhow a
decision tree approach may be applied tO
both chemical safety eval-
uation and P450 specifici-
ty, respectively.
The decision tree
approach to toxicity
screening presented in
Figure 3 has been con-
structed on the basis of
several studies on predict-
ing rodent carcinogenici-
ty as conducted in this
laboratory. We have pro-
posed that this may also
be of benefit in human
risk assessment (89).
Figure 4 represents a
decision tree for deter-
mining the likely P450
isoform speciflcity of a
given chemical; this is
based on extensive studies
on the structural charac-
teristics of substantial
numbers of P450 sub-
strates and inducers (90).
Although there are differ-
ences in the levels of
P450 families and sub-
families, including tissue
distribution, between
humans and other animal
species, the decision tree in
Figure 4 can be employed
across mammalian species
because the particular
P450 substrate specificities
tend to remain relatively
well-conserved when one
compares specificities for
individual P450 families
and subfamilies. We hope
that workers in the field
will find these decision
trees ot use in the screen-
ing ofchemicals for potential toxicity, where
possible species differences in metabolism
may be attributable in part to the relative
activities oforthologous P450 isoforms.
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protonatable nitrogen atom 5-7 Afrom the site of metabolism. CYP2C9
substrates generally possess a hydrogen bond donor/acceptor atom 5-8A
from the site of metabolism. Some compounds can be substrates for more
than one P450, especially where there is overlapping specificity. This
scheme does not necessarily apply to steroids and other endogenous
chemicals. which can be substrates of several P450s.
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ATTENTION EDUCATORS
For as little as $3.09* per year/per user, your students can have full
Internet access to the Environmental Health Information Service (EHIS)!
THE EHIS OFFERS ONLINE, SEARCHABLE ACCESS TO:
* Environmental Health Perspectives
* EnvironmentalHealth Perspectives
Supplements
* National Toxicology Program Technical
and Toxicology Reports
.., A. . ...... .. S ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ .......... * Report on Carcinogens
* Chemical Health and Safety Database
* Historical Control Database
For more information on ordering see
http://ehis.niehs.nih.gov
or call 1-800-315-3010.
*Price is based on Multiple User
Internet Access-Education Accounts
including full Internet access for . Iu
250 users and printcopies of EHP,
EHPSupplements, and NTP Reports.
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